Q-omics provides the consensus-scored GLULP6 profile across patient tissues and cancer cell-line models. GLULP6 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GLULP6 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, GLULP6 RNA expression shows 5,853 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, LIHC, and STAD as cancer lineages where GLULP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLULP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLULP6 survival associations across molecular data types. GLULP6 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLULP6 RNA expression–survival associations across cancer types. High GLULP6 expression shows unfavorable associations in MESO, HNSC, SKCM, STAD, UCS and THYM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for GLULP6 RNA expression.
This table summarizes GLULP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for GLULP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLULP6 shows lower tumor expression in ESCA and higher tumor expression in LIHC. The LIHC box plot shows higher GLULP6 RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .005).
This table shows molecular features associated with GLULP6 in patient tissues and cancer cell lines. In patient samples, GLULP6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
